The company develops plant-based vaccines and antibody therapeutics targeting pathogens linked to global health challenges, including cancer and emerging diseases. By utilizing agricultural biotechnology, it aims to enhance vaccine accessibility and efficacy for widespread medical use.
Funding
$30K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional vaccine and antibody production methods often rely on mammalian cell cultures, which can be expensive, time-consuming, and require specialized facilities. This can limit the scalability and accessibility of vaccines and therapeutics, particularly in resource-limited settings. Furthermore, the risk of contamination with mammalian pathogens poses a challenge to the safety and purity of these products.
Solution
This company leverages plant-based biotechnology to produce vaccines and antibody therapeutics, offering a scalable and cost-effective alternative to conventional methods. By utilizing plants as bioreactors, the company can rapidly produce large quantities of target proteins, reducing manufacturing costs and timelines. The plant-based system also minimizes the risk of mammalian pathogen contamination, enhancing product safety. This approach aims to improve the accessibility and affordability of vaccines and therapeutics for a wide range of diseases, including cancer and emerging infectious diseases.
Target Audience
The primary target audience includes pharmaceutical companies, global health organizations, and government agencies seeking cost-effective and scalable solutions for vaccine and antibody production.
Features
- Plant-based expression system for rapid and scalable production of recombinant proteins
- Production of vaccines and antibody therapeutics targeting cancer and emerging infectious diseases
- Reduced manufacturing costs compared to traditional mammalian cell culture methods
- Minimized risk of mammalian pathogen contamination
- Potential for oral delivery of vaccines through plant tissues
- Streamlined regulatory pathway due to the safety profile of plant-based products